WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS - News) announced today that its product candidate AI-850 has a comparable pharmocokinetic profile to the breast cancer drug Abraxane® based upon human data available in publications on each drug. AI-850 is Acusphere’s patented formulation of paclitaxel, the active ingredient in Abraxane. Drug product candidates that are confirmed to have equivalent pharmacokinetics in a human study may be eligible for regulatory approval as a bioequivalent, with an accelerated development timeline, since Phase 2 and 3 human clinical trials are usually not required. Abraxane for Injectable Suspension, which is marketed under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca, generated $150 million in revenues in the six months ended June 30, 2007, and is projected by some analysts to reach revenues of $1 billion by 2013.
